Antiviral neutralizing antibodies: from in vitro to in vivo activity
DR Burton - Nature Reviews Immunology, 2023 - nature.com
Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …
Neutralization, effector function and immune imprinting of Omicron variants
Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots
in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on …
in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on …
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19
The world is in need of next-generation COVID-19 vaccines. Although first-generation
injectable COVID-19 vaccines continue to be critical tools in controlling the current global …
injectable COVID-19 vaccines continue to be critical tools in controlling the current global …
Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination
Group 2B β-coronaviruses (sarbecoviruses) have caused regional and global epidemics in
modern history. Here, we evaluate the mechanisms of cross-sarbecovirus protective …
modern history. Here, we evaluate the mechanisms of cross-sarbecovirus protective …
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy
KA Moore, T Leighton, JT Ostrowsky, CJ Anderson… - Vaccine, 2023 - Elsevier
Broadly protective coronavirus vaccines are an important tool for protecting against future
SARS-CoV-2 variants and could play a critical role in mitigating the impact of future …
SARS-CoV-2 variants and could play a critical role in mitigating the impact of future …
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …
binding domain (RBD) hot spots. Their impact on viral infection, transmission, and efficacy of …
[HTML][HTML] A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ. 1.1 and XBB. 1.5 infection and disease in mice and hamsters
We previously described a nasally delivered monovalent adenoviral-vectored SARS-CoV-2
vaccine (ChAd-SARS-CoV-2-S, targeting Wuhan-1 spike [S]; iNCOVACC®) that is currently …
vaccine (ChAd-SARS-CoV-2-S, targeting Wuhan-1 spike [S]; iNCOVACC®) that is currently …
[HTML][HTML] Diverging maternal and infant cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy
EH Adhikari, P Lu, Y jin Kang, AR McDonald… - bioRxiv, 2023 - ncbi.nlm.nih.gov
Immunization in pregnancy is a critical tool that can be leveraged to protect the infant with an
immature immune system but how vaccine-induced antibodies transfer to the placenta and …
immature immune system but how vaccine-induced antibodies transfer to the placenta and …
[PDF][PDF] A. Aanleiding OMT-V en doelstelling
M van Volksgezondheid, W en Sport, M Sonnema… - eumonitor.nl
Doelstelling van het OMT-V op 17 februari 2023 was om een advies uit te brengen over de
noodzaak van aanvullende COVID-19-revaccinaties in het voorjaar van 2023. Op 27 januari …
noodzaak van aanvullende COVID-19-revaccinaties in het voorjaar van 2023. Op 27 januari …